Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: THC stock price vs ACAD: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ACAD's multiple
Needs ACAD P/E.
Implied fair value · at THC's multiple
Needs THC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TENET HEALTHCARE CORP · implied price per share
Bear
$105.38
Base
$143.97
Bull
$194.22
ACADIA PHARMACEUTICALS INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
HCA Healthcare, Inc.
THC vs HCA
UNIVERSAL HEALTH SERVICES INC
THC vs UHS
COMMUNITY HEALTH SYSTEMS INC
THC vs CYH
Encompass Health Corp
THC vs EHC
SELECT MEDICAL HOLDINGS CORP
THC vs SEM
Acadia Healthcare Company, Inc.
THC vs ACHC
SUPERNUS PHARMACEUTICALS, INC.
THC vs SUPN
Sage Therapeutics, Inc.
THC vs SAGE
Jazz Pharmaceuticals plc
THC vs JAZZ
Alkermes plc.
THC vs ALKS
Harmony Biosciences Holdings, Inc.
THC vs HRMY
Krystal Biotech, Inc.
THC vs KRYS
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe THC can sustain its stronger margins and ROIC while de-risking leverage, then hold or accumulate on weakness because the business quality is better than ACAD on operating efficiency even though the P/E screen points to downside.
THC's current price of $259.32 sits below its historical band midpoint and well below the DCF range, but ACAD comparison is mixed because THC trades at a higher P/E than ACAD. The implied price of $193.76 suggests 25.3% downside on the P/E basis, reflecting a valuation that is not obviously cheap relative to ACAD.
Supporting Metrics
